首页 > 最新文献

Cardiology in Review最新文献

英文 中文
Frank J. Veith, MD: Vascular Surgeon, Pioneer, Leader.
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-10-24 DOI: 10.1097/CRD.0000000000000809
Samantha Fountain, George Hines, Reese Wain
{"title":"Frank J. Veith, MD: Vascular Surgeon, Pioneer, Leader.","authors":"Samantha Fountain, George Hines, Reese Wain","doi":"10.1097/CRD.0000000000000809","DOIUrl":"https://doi.org/10.1097/CRD.0000000000000809","url":null,"abstract":"","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":"33 2","pages":"99-101"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Technology Promote Patient-Centered Care in Cardiac Rehabilitation. 技术进步促进以患者为中心的心脏康复护理。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-08-21 DOI: 10.1097/CRD.0000000000000599
Dana Ben-Tzur, Solomon Sabovich, Yeshayahu Hutzler, Jordan Rimon, Sima Zach, Maor Epstein, Brian Vadasz, Camilla V Diniz, Irene Nabutovsky, Robert Klempfner, Sigal Eilat-Adar, Itzhak Gabizon, Doron M Menachemi, Liza Grosman-Rimon

Patient-centered health care (PCC) is a framework of clinical care focused on the patient's individual health care needs. In particular, it emphasizes the development of a partnership between the patient, physician, and healthcare workers to actively involve and empower the patient in their health care decisions. Additionally, PCC goals include ensuring access to care, emotional support, engaging patient support systems, physical comfort, and continuity of care. Technology also provides a platform to engage patients and their families in their care and can be a useful tool to gauge their level of interest, knowledge, and motivations to adequately educate them on the many factors that contribute to their disease, including diet, exercise, medication adherence, psychological support, and early symptom detection. In this article, we summarize the importance of technology in promoting PCC in cardiac rehabilitation and the impact technology may have on the different aspects of patient and physician relationships. Modern technological devices including smartphones, tablets, wearables, and other internet-enabled devices have been shown to help patient-staff communication, cater to patients' individual needs, increase access to health care, and implement aspects of PCC domains.

以患者为中心的医疗保健(PCC)是临床护理的一个框架,关注患者的个人医疗保健需求。特别是,它强调发展患者、医生和保健工作者之间的伙伴关系,使患者积极参与其保健决策并赋予其权力。此外,PCC的目标还包括确保获得护理、情感支持、参与患者支持系统、身体舒适和护理的连续性。技术还提供了一个平台,让患者及其家属参与到他们的护理中来,并可以成为衡量他们的兴趣水平、知识水平和动机的有用工具,从而充分教育他们了解导致其疾病的许多因素,包括饮食、运动、药物依从性、心理支持和早期症状检测。在本文中,我们总结了技术在促进PCC在心脏康复中的重要性,以及技术可能对医患关系的不同方面产生的影响。包括智能手机、平板电脑、可穿戴设备和其他支持互联网的设备在内的现代技术设备已被证明有助于患者与医护人员的沟通,满足患者的个人需求,增加获得医疗保健的机会,并实现PCC领域的各个方面。
{"title":"Advances in Technology Promote Patient-Centered Care in Cardiac Rehabilitation.","authors":"Dana Ben-Tzur, Solomon Sabovich, Yeshayahu Hutzler, Jordan Rimon, Sima Zach, Maor Epstein, Brian Vadasz, Camilla V Diniz, Irene Nabutovsky, Robert Klempfner, Sigal Eilat-Adar, Itzhak Gabizon, Doron M Menachemi, Liza Grosman-Rimon","doi":"10.1097/CRD.0000000000000599","DOIUrl":"10.1097/CRD.0000000000000599","url":null,"abstract":"<p><p>Patient-centered health care (PCC) is a framework of clinical care focused on the patient's individual health care needs. In particular, it emphasizes the development of a partnership between the patient, physician, and healthcare workers to actively involve and empower the patient in their health care decisions. Additionally, PCC goals include ensuring access to care, emotional support, engaging patient support systems, physical comfort, and continuity of care. Technology also provides a platform to engage patients and their families in their care and can be a useful tool to gauge their level of interest, knowledge, and motivations to adequately educate them on the many factors that contribute to their disease, including diet, exercise, medication adherence, psychological support, and early symptom detection. In this article, we summarize the importance of technology in promoting PCC in cardiac rehabilitation and the impact technology may have on the different aspects of patient and physician relationships. Modern technological devices including smartphones, tablets, wearables, and other internet-enabled devices have been shown to help patient-staff communication, cater to patients' individual needs, increase access to health care, and implement aspects of PCC domains.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"160-165"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10051672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitral Annular Disjunction: A Scoping Review. 二尖瓣环形分离:范围回顾。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-08-03 DOI: 10.1097/CRD.0000000000000594
Sushan Gupta, Ahmad Shihabi, Mihir Kishore Patil, Timothy Shih

Mitral annular disjunction (MAD) is the atrial displacement of the mitral valve (MV) hinge point, especially along the posterior mitral leaflet, which leads to inhomogeneous blood flow into the left ventricle, causing chronic fibrotic changes, malignant arrhythmias, and even sudden cardiac arrest. Some studies suggest that MAD is a part of normal heart morphology; however, the origin is still controversial. MAD commonly occurs with MV prolapse and myxomatous degenerative MV disease. In almost 20% of cases, MAD can occur independently as well. The prevalence of MAD in normal hearts varies from 8.6% to 96%, depending on the imaging modality and the cutoff used to define MAD. Transthoracic echocardiography is often the initial screening test, but the low sensitivity of transthoracic echocardiography to identify MAD makes it easy to miss the diagnosis altogether. More advanced imaging, especially cardiac MRI, is the gold standard for diagnosing MAD and risk stratification. MAD is an independent predictor of malignant arrhythmia. Among patients with MAD, risk stratification is based on the age at diagnosis, previous syncopal attacks, premature ventricular contractions, papillary muscle fibrosis, and longitudinal disjunction distance. Most asymptomatic patients are managed conservatively; however, radiofrequency ablation should be considered in patients with high-risk or symptomatic MAD due to the risk of ventricular arrhythmias and sudden cardiac death.

二尖瓣环分离(MAD)是二尖瓣(MV)铰链点的心房移位,特别是沿二尖瓣后小叶,导致血流不均匀进入左心室,引起慢性纤维化改变,恶性心律失常,甚至心脏骤停。一些研究表明,MAD是正常心脏形态的一部分;然而,其起源仍有争议。MAD常见于中压脱垂和粘液瘤性中压退行性疾病。在几乎20%的病例中,MAD也可以独立发生。正常心脏中MAD的患病率从8.6%到96%不等,这取决于成像方式和用于定义MAD的截止时间。经胸超声心动图通常是最初的筛查试验,但经胸超声心动图识别MAD的低灵敏度使得它很容易完全错过诊断。更先进的成像,特别是心脏MRI,是诊断MAD和风险分层的金标准。MAD是恶性心律失常的独立预测因子。在MAD患者中,危险分层是基于诊断时的年龄、既往晕厥发作、室性早搏、乳头状肌纤维化和纵向分离距离。大多数无症状患者采用保守治疗;然而,由于室性心律失常和心源性猝死的风险,对于高危或症状性MAD患者应考虑射频消融。
{"title":"Mitral Annular Disjunction: A Scoping Review.","authors":"Sushan Gupta, Ahmad Shihabi, Mihir Kishore Patil, Timothy Shih","doi":"10.1097/CRD.0000000000000594","DOIUrl":"10.1097/CRD.0000000000000594","url":null,"abstract":"<p><p>Mitral annular disjunction (MAD) is the atrial displacement of the mitral valve (MV) hinge point, especially along the posterior mitral leaflet, which leads to inhomogeneous blood flow into the left ventricle, causing chronic fibrotic changes, malignant arrhythmias, and even sudden cardiac arrest. Some studies suggest that MAD is a part of normal heart morphology; however, the origin is still controversial. MAD commonly occurs with MV prolapse and myxomatous degenerative MV disease. In almost 20% of cases, MAD can occur independently as well. The prevalence of MAD in normal hearts varies from 8.6% to 96%, depending on the imaging modality and the cutoff used to define MAD. Transthoracic echocardiography is often the initial screening test, but the low sensitivity of transthoracic echocardiography to identify MAD makes it easy to miss the diagnosis altogether. More advanced imaging, especially cardiac MRI, is the gold standard for diagnosing MAD and risk stratification. MAD is an independent predictor of malignant arrhythmia. Among patients with MAD, risk stratification is based on the age at diagnosis, previous syncopal attacks, premature ventricular contractions, papillary muscle fibrosis, and longitudinal disjunction distance. Most asymptomatic patients are managed conservatively; however, radiofrequency ablation should be considered in patients with high-risk or symptomatic MAD due to the risk of ventricular arrhythmias and sudden cardiac death.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"145-152"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9929936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of the Etiology, Diagnosis, and Therapy of Left Atrial Thrombus. 左房血栓的病因、诊断和治疗综述。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-08-02 DOI: 10.1097/CRD.0000000000000592
Jared M Feldman, Andy Wang, William H Frishman, Wilbert S Aronow

Thrombi in the left atrial appendage (LAA) are an important cause of systemic thromboembolism in patients with atrial fibrillation. The gold standard for the diagnosis of LAA thrombi is a transesophageal echocardiogram, although cardiac multidetector computed tomography, intracardiac echocardiogram, and cardiac magnetic resonance imaging are alternative diagnostic imaging modalities. When an LAA thrombus is diagnosed, effective anticoagulation is recommended for at least 3 weeks or until thrombus resolution is confirmed on repeat transesophageal echocardiogram. Recent prospective research shows the efficacy of nonvitamin K oral anticoagulants in the treatment of LAA thrombus, which offers a promising alternative to vitamin K antagonists. As an alternative approach, left atrial aspiration thrombectomy has been described in case reports, though there is limited evidence comparing its efficacy to anticoagulation alone.

左心耳血栓(LAA)是心房颤动患者发生系统性血栓栓塞的重要原因。诊断LAA血栓的金标准是经食管超声心动图,尽管心脏多探测器计算机断层扫描、心内超声心动图和心脏磁共振成像是可替代的诊断成像方式。当诊断出LAA血栓时,建议有效抗凝治疗至少3周,或直到重复经食管超声心动图确认血栓消退。最近的前瞻性研究显示非维生素K口服抗凝剂治疗LAA血栓的疗效,这为维生素K拮抗剂提供了一个有希望的替代方案。作为一种替代方法,左心房抽吸取栓术在病例报告中有描述,尽管将其与单独抗凝的疗效进行比较的证据有限。
{"title":"Review of the Etiology, Diagnosis, and Therapy of Left Atrial Thrombus.","authors":"Jared M Feldman, Andy Wang, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000592","DOIUrl":"10.1097/CRD.0000000000000592","url":null,"abstract":"<p><p>Thrombi in the left atrial appendage (LAA) are an important cause of systemic thromboembolism in patients with atrial fibrillation. The gold standard for the diagnosis of LAA thrombi is a transesophageal echocardiogram, although cardiac multidetector computed tomography, intracardiac echocardiogram, and cardiac magnetic resonance imaging are alternative diagnostic imaging modalities. When an LAA thrombus is diagnosed, effective anticoagulation is recommended for at least 3 weeks or until thrombus resolution is confirmed on repeat transesophageal echocardiogram. Recent prospective research shows the efficacy of nonvitamin K oral anticoagulants in the treatment of LAA thrombus, which offers a promising alternative to vitamin K antagonists. As an alternative approach, left atrial aspiration thrombectomy has been described in case reports, though there is limited evidence comparing its efficacy to anticoagulation alone.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"135-138"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9911868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiphospholipid Syndrome: Thrombotic and Vascular Complications. 抗磷脂综合征:血栓和血管并发症。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-08-21 DOI: 10.1097/CRD.0000000000000590
Stephen Windisch, Julia Y Ash, William H Frishman

Antiphospholipid syndrome is a rare, autoimmune thrombophilia defined by vascular thrombosis and pregnancy morbidity, in the setting of documented persistent antiphospholipid antibodies including the lupus anticoagulant, anticardiolipin antibodies, or anti-β2 glycoprotein I antibodies. The presence of antiphospholipid antibodies can be completely asymptomatic, or they can lead to clinical manifestations as severe as catastrophic antiphospholipid syndrome, which involves widespread coagulopathy over a very short period of time. The degree of risk associated with antiphospholipid syndrome depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. The current standard treatment for unprovoked thrombosis is long-term warfarin. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin in pregnant patients. The use of direct oral anticoagulants in patients with antiphospholipid syndrome is still being debated. Their use is generally contraindicated, especially in high-risk patients, such as those with all 3 antiphospholipid antibodies present, but they may potentially be of some use in some low-risk patients.

抗磷脂综合征是一种罕见的自身免疫性血栓形成,由血管血栓形成和妊娠发病率定义,在有记录的持续抗磷脂抗体的环境中,包括狼疮抗凝血剂、抗心磷脂抗体或抗β2糖蛋白I抗体。抗磷脂抗体的存在可以是完全无症状的,也可以导致严重的临床表现,如灾难性抗磷脂综合征,在很短的时间内包括广泛的凝血功能障碍。与抗磷脂综合征相关的危险程度取决于抗磷脂抗体谱的特征和其他血栓危险因素的存在。目前非诱发性血栓形成的标准治疗是长期使用华法林。治疗预防复发产科并发症是低剂量阿司匹林和预防性肝素在怀孕患者。在抗磷脂综合征患者中直接使用口服抗凝剂仍存在争议。它们的使用通常是禁忌的,特别是在高风险患者中,例如所有3种抗磷脂抗体都存在的患者,但它们可能对一些低风险患者有一些潜在的用途。
{"title":"Antiphospholipid Syndrome: Thrombotic and Vascular Complications.","authors":"Stephen Windisch, Julia Y Ash, William H Frishman","doi":"10.1097/CRD.0000000000000590","DOIUrl":"10.1097/CRD.0000000000000590","url":null,"abstract":"<p><p>Antiphospholipid syndrome is a rare, autoimmune thrombophilia defined by vascular thrombosis and pregnancy morbidity, in the setting of documented persistent antiphospholipid antibodies including the lupus anticoagulant, anticardiolipin antibodies, or anti-β2 glycoprotein I antibodies. The presence of antiphospholipid antibodies can be completely asymptomatic, or they can lead to clinical manifestations as severe as catastrophic antiphospholipid syndrome, which involves widespread coagulopathy over a very short period of time. The degree of risk associated with antiphospholipid syndrome depends on the characteristics of the antiphospholipid antibody profile and on the presence of additional thrombotic risk factors. The current standard treatment for unprovoked thrombosis is long-term warfarin. Treatment to prevent recurrent obstetric complications is low-dose aspirin and prophylactic heparin in pregnant patients. The use of direct oral anticoagulants in patients with antiphospholipid syndrome is still being debated. Their use is generally contraindicated, especially in high-risk patients, such as those with all 3 antiphospholipid antibodies present, but they may potentially be of some use in some low-risk patients.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"139-144"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10051674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review and Key Takeaways of the 2021 Percutaneous Coronary Intervention Guidelines. 2021年经皮冠状动脉介入治疗指南的回顾和关键要点。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-09-20 DOI: 10.1097/CRD.0000000000000608
Haris Patail, Atul Bali, Tanya Sharma, William H Frishman, Wilbert S Aronow

The 2021 Percutaneous Coronary Intervention guidelines completed by American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions provide a set of guidelines regarding revascularization strategies. With emphasis on equity of care, multidisciplinary heart team use, revascularization for acute coronary syndrome, and stable ischemic heart disease, the guidelines create a thorough framework with recommendations regarding therapeutic strategies. In this comprehensive review, our aim is to summarize the 2021 revascularization guidelines and analyze key points regarding each recommendation.

美国心脏病学院/美国心脏协会/心血管血管造影和介入学会完成的2021年经皮冠状动脉介入治疗指南提供了一套关于血运重建策略的指南。该指南强调护理的公平性、多学科心脏团队的使用、急性冠状动脉综合征的血运重建和稳定的缺血性心脏病,为治疗策略提供了全面的建议。在这篇全面综述中,我们的目的是总结2021年血运重建指南,并分析每项建议的要点。
{"title":"Review and Key Takeaways of the 2021 Percutaneous Coronary Intervention Guidelines.","authors":"Haris Patail, Atul Bali, Tanya Sharma, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000608","DOIUrl":"10.1097/CRD.0000000000000608","url":null,"abstract":"<p><p>The 2021 Percutaneous Coronary Intervention guidelines completed by American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions provide a set of guidelines regarding revascularization strategies. With emphasis on equity of care, multidisciplinary heart team use, revascularization for acute coronary syndrome, and stable ischemic heart disease, the guidelines create a thorough framework with recommendations regarding therapeutic strategies. In this comprehensive review, our aim is to summarize the 2021 revascularization guidelines and analyze key points regarding each recommendation.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"178-186"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Concise Review of Marfan Syndrome with a Congenital Cardiac Surgery Focus. 以先天性心脏外科为重点的马凡氏综合症简明综述。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-10-24 DOI: 10.1097/CRD.0000000000000619
Andrew D Vogel, Gabriela M Galan, T Konrad Rajab

Marfan syndrome is named after Antoine Marfan, who described a 5-year-old child with congenital elongation of the digits and other skeletal abnormalities in 1896. While Marfan syndrome is a systemic connective tissue disorder predominantly involving the skeletal, cardiovascular, and ocular systems, the cardiovascular system presents the most life-threatening complications. Most cardiovascular pathologies surround the left ventricular outflow tract and aorta, with aortic dissection requiring emergent surgical management to the progression of mitral regurgitation requiring elective surgery. Intensive care management, along with a tailored approach to the surgical management of a patient with Marfan syndrome, is critical to their survival. Current surgical operations for patients include aortic root surgery, valve-sparing root replacements, aortic root replacements with conduits, and mitral valve repairs. Further research is necessary to determine the molecular, endovascular, pharmaceutical, and surgical management of Marfan syndrome. This review attempts to concisely discuss the diagnosis, complications, and medical and intensive care management of Marfan syndrome while further divulging on the surgical management of those with this disease process.

马凡综合征是以安托万-马凡的名字命名的,他在 1896 年描述了一名患有先天性手指伸长和其他骨骼畸形的 5 岁儿童。虽然马凡综合征是一种全身性结缔组织疾病,主要涉及骨骼、心血管和眼部系统,但心血管系统的并发症最危及生命。大多数心血管病变围绕着左心室流出道和主动脉,主动脉夹层需要紧急手术治疗,二尖瓣反流的进展则需要择期手术。重症监护管理以及为马凡氏综合征患者量身定制的手术治疗方法对患者的存活至关重要。目前为患者实施的手术包括主动脉根部手术、保瓣根部置换术、带导管的主动脉根部置换术和二尖瓣修复术。要确定马凡氏综合征的分子、血管内、药物和外科治疗方法,还需要进一步的研究。本综述试图简明扼要地讨论马凡氏综合征的诊断、并发症、内科和重症监护管理,同时进一步介绍该疾病患者的外科治疗。
{"title":"A Concise Review of Marfan Syndrome with a Congenital Cardiac Surgery Focus.","authors":"Andrew D Vogel, Gabriela M Galan, T Konrad Rajab","doi":"10.1097/CRD.0000000000000619","DOIUrl":"10.1097/CRD.0000000000000619","url":null,"abstract":"<p><p>Marfan syndrome is named after Antoine Marfan, who described a 5-year-old child with congenital elongation of the digits and other skeletal abnormalities in 1896. While Marfan syndrome is a systemic connective tissue disorder predominantly involving the skeletal, cardiovascular, and ocular systems, the cardiovascular system presents the most life-threatening complications. Most cardiovascular pathologies surround the left ventricular outflow tract and aorta, with aortic dissection requiring emergent surgical management to the progression of mitral regurgitation requiring elective surgery. Intensive care management, along with a tailored approach to the surgical management of a patient with Marfan syndrome, is critical to their survival. Current surgical operations for patients include aortic root surgery, valve-sparing root replacements, aortic root replacements with conduits, and mitral valve repairs. Further research is necessary to determine the molecular, endovascular, pharmaceutical, and surgical management of Marfan syndrome. This review attempts to concisely discuss the diagnosis, complications, and medical and intensive care management of Marfan syndrome while further divulging on the surgical management of those with this disease process.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"166-170"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Atrial Appendage Closure: What Do We Know? 左心耳闭合:我们知道些什么?
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-08-29 DOI: 10.1097/CRD.0000000000000601
Savalan Babapoor-Farrokhran, Jafar Alzubi, Zachary Port, Risheek Kaul, Roozbeh Tarighati Rasekhi, Ali Babapour Farrokhran, Naveen Sooknanan, Philip C Wiener, Ola Khraisha, William H Frishman, Sumeet K Mainigi, Wilbert S Aronow

Atrial fibrillation (AF) is the most common arrhythmia in the United States and the most common cause of embolic cerebrovascular events, with the majority of these thrombi originating in the left atrial appendage. The left atrial appendage (LAA) has separate developmental, ultrastructural, and physiological characteristics from the left atrium. Although LAA anatomy is highly variable, it can be categorized into 4 types: cactus, cauliflower, chicken wing, and windsock. The cauliflower type is associated with higher stroke risk in patients with nonvalvular AF. Although the cornerstone of therapy to prevent embolic strokes from AF has been anticoagulation with thrombin inhibitors, a large group of patients are unable to tolerate anticoagulation due to bleeding. This has led to the development and advancement of multiple surgical and percutaneous LAA closure devices to prevent embolic cerebrovascular accidents without the need for anticoagulation. In this article, we discuss the outcomes of major studies that utilized surgical LAA occlusion and its effectiveness. Furthermore, we summarize nonsurgical methods of LAA closure and future directions regarding LAA closure.

心房颤动(AF)是美国最常见的心律失常,也是栓塞性脑血管事件的最常见原因,其中大多数血栓起源于左心房附件。左心房附件(LAA)与左心房具有不同的发育、超微结构和生理特征。虽然LAA的解剖结构变化很大,但它可以分为4种:仙人掌、花椰菜、鸡翅和风袜。花椰菜型与非瓣膜性房颤患者较高的卒中风险相关。尽管预防房颤栓塞性卒中的治疗基础是使用凝血酶抑制剂抗凝,但大量患者由于出血而无法耐受抗凝。这导致了多种手术和经皮LAA闭合装置的发展和进步,以防止栓塞性脑血管事故而无需抗凝。在本文中,我们讨论了主要研究的结果,利用手术LAA闭塞和它的有效性。此外,我们总结了非手术缝合LAA的方法和未来的发展方向。
{"title":"Left Atrial Appendage Closure: What Do We Know?","authors":"Savalan Babapoor-Farrokhran, Jafar Alzubi, Zachary Port, Risheek Kaul, Roozbeh Tarighati Rasekhi, Ali Babapour Farrokhran, Naveen Sooknanan, Philip C Wiener, Ola Khraisha, William H Frishman, Sumeet K Mainigi, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000601","DOIUrl":"10.1097/CRD.0000000000000601","url":null,"abstract":"<p><p>Atrial fibrillation (AF) is the most common arrhythmia in the United States and the most common cause of embolic cerebrovascular events, with the majority of these thrombi originating in the left atrial appendage. The left atrial appendage (LAA) has separate developmental, ultrastructural, and physiological characteristics from the left atrium. Although LAA anatomy is highly variable, it can be categorized into 4 types: cactus, cauliflower, chicken wing, and windsock. The cauliflower type is associated with higher stroke risk in patients with nonvalvular AF. Although the cornerstone of therapy to prevent embolic strokes from AF has been anticoagulation with thrombin inhibitors, a large group of patients are unable to tolerate anticoagulation due to bleeding. This has led to the development and advancement of multiple surgical and percutaneous LAA closure devices to prevent embolic cerebrovascular accidents without the need for anticoagulation. In this article, we discuss the outcomes of major studies that utilized surgical LAA occlusion and its effectiveness. Furthermore, we summarize nonsurgical methods of LAA closure and future directions regarding LAA closure.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"153-159"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10103705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PCSK9 Inhibitors - A New Hope for Dyslipidemia in HIV. PCSK9抑制剂——治疗HIV血脂异常的新希望
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2023-11-29 DOI: 10.1097/CRD.0000000000000587
Sanjana Datla, Sundeep Kumar

Cardiovascular disease has become increasingly prevalent in the HIV population. Antiretroviral therapy and HIV itself independently increase the risk of dyslipidemia. While statins are currently the predominant therapy to treat dyslipidemia in HIV patients, drug-drug interactions and adverse drug events can limit their use. Proprotein convertase subtilisin/kexin type 9 inhibitors have shown promising results in preliminary trials by significantly reducing low density lipoprotein and other atherogenic lipid levels. They should be considered as an early intervention alongside statins in HIV patients with dyslipidemia.

心血管疾病在艾滋病毒人群中越来越普遍。抗逆转录病毒治疗和艾滋病毒本身独立增加血脂异常的风险。虽然他汀类药物目前是治疗HIV患者血脂异常的主要药物,但药物相互作用和药物不良事件可能限制其使用。蛋白转化酶枯草杆菌素/kexin 9型抑制剂在初步试验中显示出有希望的结果,可以显著降低低密度脂蛋白和其他致动脉粥样硬化的脂质水平。对于患有血脂异常的HIV患者,应考虑将其与他汀类药物一起作为早期干预措施。
{"title":"PCSK9 Inhibitors - A New Hope for Dyslipidemia in HIV.","authors":"Sanjana Datla, Sundeep Kumar","doi":"10.1097/CRD.0000000000000587","DOIUrl":"10.1097/CRD.0000000000000587","url":null,"abstract":"<p><p>Cardiovascular disease has become increasingly prevalent in the HIV population. Antiretroviral therapy and HIV itself independently increase the risk of dyslipidemia. While statins are currently the predominant therapy to treat dyslipidemia in HIV patients, drug-drug interactions and adverse drug events can limit their use. Proprotein convertase subtilisin/kexin type 9 inhibitors have shown promising results in preliminary trials by significantly reducing low density lipoprotein and other atherogenic lipid levels. They should be considered as an early intervention alongside statins in HIV patients with dyslipidemia.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"112-113"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138450925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Implication of Preprocedural Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis. 接受经导管主动脉瓣植入术的重度主动脉瓣狭窄患者术前肺动脉高压的预后影响:系统综述与 Meta 分析》。
IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-01 Epub Date: 2024-01-29 DOI: 10.1097/CRD.0000000000000583
Mahmood Emami Meybodi, Atefe Bamarinejad, Fateme Bamarinejad, Amir Parsa Abhari, Mohammad Fakhrolmobasheri, Fareheh Khosravi Larijani, Shidrokh Nasiri, Davood Shafie

Pulmonary hypertension (PH) is a common comorbidity in patients with aortic stenosis (AS) who are candidates for transcatheter aortic valve implantation (TAVI). Herein, we sought to elucidate the prognostic value of preprocedural PH on the early and late mortality after TAVI. The Cochrane Library, Scopus, PubMed, Web of Science, Embase, and ProQuest were screened using a predefined search query. We considered odds ratios (ORs) as the measure of effect. Meta-regression analysis was applied to investigate the potential impact of baseline characteristics on the outcomes. Egger's and Begg's tests were used to assess the publication bias. Thirty-three studies comprising 34 datasets representing 68,435 patients were included in the analysis. Regardless of the definition and severity of PH, pooled data analysis indicated that preprocedural PH was associated with higher cardiac and overall 30-day [OR, 1.45 (1.15-1.82) and OR, 1.75 (1.42-2.17), respectively], and 1-year mortality [OR, 1.63 (1.35-1.96) and OR, 1.59 (1.38-1.82), respectively]. Meta-regression analysis demonstrated that older age, higher New York Heart Association function class, history of hypertension, diabetes, and lower left ventricular ejection fraction were predictors of higher mortality rate following TAVI. Moreover, we found that preprocedural PH is significantly associated with higher in-hospital mortality and 30-day acute kidney injury. Our results demonstrated that preprocedural PH is associated with higher early and late cardiac and overall mortality following TAVI; however, this finding is limited regarding the considerable inconsistency in the definition of PH and PH severity among studies.

肺动脉高压(PH)是经导管主动脉瓣植入术(TAVI)候选患者中常见的合并症。在此,我们试图阐明术前 PH 对 TAVI 术后早期和晚期死亡率的预后价值。我们使用预定义的搜索查询筛选了 Cochrane Library、Scopus、PubMed、Web of Science、Embase 和 ProQuest。我们将几率比(ORs)作为衡量效果的指标。元回归分析用于研究基线特征对结果的潜在影响。埃格氏和贝格氏检验用于评估发表偏倚。本次分析共纳入了 33 项研究,包括 34 个数据集,代表了 68,435 名患者。无论PH的定义和严重程度如何,汇总数据分析显示,术前PH与较高的心脏死亡率和30天总死亡率[OR,分别为1.45(1.15-1.82)和1.75(1.42-2.17)]以及1年死亡率[OR,分别为1.63(1.35-1.96)和1.59(1.38-1.82)]相关。元回归分析表明,年龄较大、纽约心脏协会功能分级较高、高血压病史、糖尿病和左心室射血分数较低是预测 TAVI 术后死亡率较高的因素。此外,我们还发现术前 PH 与较高的院内死亡率和 30 天急性肾损伤显著相关。我们的研究结果表明,术前 PH 与 TAVI 术后较高的早期和晚期心脏死亡率及总死亡率有关;但是,由于不同研究对 PH 的定义和 PH 的严重程度存在很大的不一致,因此这一发现还存在一定的局限性。
{"title":"Prognostic Implication of Preprocedural Pulmonary Hypertension in Patients with Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-analysis.","authors":"Mahmood Emami Meybodi, Atefe Bamarinejad, Fateme Bamarinejad, Amir Parsa Abhari, Mohammad Fakhrolmobasheri, Fareheh Khosravi Larijani, Shidrokh Nasiri, Davood Shafie","doi":"10.1097/CRD.0000000000000583","DOIUrl":"10.1097/CRD.0000000000000583","url":null,"abstract":"<p><p>Pulmonary hypertension (PH) is a common comorbidity in patients with aortic stenosis (AS) who are candidates for transcatheter aortic valve implantation (TAVI). Herein, we sought to elucidate the prognostic value of preprocedural PH on the early and late mortality after TAVI. The Cochrane Library, Scopus, PubMed, Web of Science, Embase, and ProQuest were screened using a predefined search query. We considered odds ratios (ORs) as the measure of effect. Meta-regression analysis was applied to investigate the potential impact of baseline characteristics on the outcomes. Egger's and Begg's tests were used to assess the publication bias. Thirty-three studies comprising 34 datasets representing 68,435 patients were included in the analysis. Regardless of the definition and severity of PH, pooled data analysis indicated that preprocedural PH was associated with higher cardiac and overall 30-day [OR, 1.45 (1.15-1.82) and OR, 1.75 (1.42-2.17), respectively], and 1-year mortality [OR, 1.63 (1.35-1.96) and OR, 1.59 (1.38-1.82), respectively]. Meta-regression analysis demonstrated that older age, higher New York Heart Association function class, history of hypertension, diabetes, and lower left ventricular ejection fraction were predictors of higher mortality rate following TAVI. Moreover, we found that preprocedural PH is significantly associated with higher in-hospital mortality and 30-day acute kidney injury. Our results demonstrated that preprocedural PH is associated with higher early and late cardiac and overall mortality following TAVI; however, this finding is limited regarding the considerable inconsistency in the definition of PH and PH severity among studies.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":"120-128"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiology in Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1